



Universiteit
Leiden
The Netherlands

The impact of non-genetic factors on drug metabolism: towards better phenotype predictions

Jong, L.M. de

Citation

Jong, L. M. de. (2025, June 5). *The impact of non-genetic factors on drug metabolism: towards better phenotype predictions*. Retrieved from <https://hdl.handle.net/1887/4249242>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4249242>

Note: To cite this publication please use the final published version (if applicable).

Chapter 4

CYP and non-CYP drug metabolizing enzyme families exhibit differential sensitivities towards proinflammatory cytokine modulation

Laura M. de Jong, Chandan Harpal, Dirk-Jan van den Berg,
Menno Hoekstra, Nienke J. Peter, Robert Rissmann,
Jesse J. Swen, Martijn L. Manson



Abstract

Compromised hepatic drug metabolism in response to proinflammatory cytokine release is primarily attributed to downregulation of cytochrome P450 (CYP) enzymes. However, whether inflammation also affects other phase I and phase II drug metabolizing enzymes (DMEs), such as the flavin monooxygenases (FMOs), carboxylesterases (CESs), and UDP glucuronosyltransferases (UGTs), remains unclear. This study aimed to decipher the impact of physiologically relevant concentrations of proinflammatory cytokines on expression and activity of phase I and phase II enzymes, to establish a hierarchy of their sensitivity as compared with the CYPs. Hereto, HepaRG cells were exposed to interleukin-6 and interleukin-1 β to measure alterations in DME gene expression (24 h) and activity (72 h). Sensitivity of DMEs toward proinflammatory cytokines was evaluated by determining IC₅₀ (potency) and I_{max} (maximal inhibition) values from the concentration-response curves. Proinflammatory cytokine treatment led to nearly complete downregulation of CYP3A4 (~98%) but was generally less efficacious at reducing gene expression of the non-CYP DME families. Importantly, FMO, CES, and UGT family members were less sensitive toward interleukin-6 induced inhibition in terms of potency, with IC₅₀ values that were 4.3- to 7.4-fold higher than CYP3A4. Similarly, 18- to 31-fold more interleukin-1 β was required to achieve 50% of the maximal downregulation of FMO3, FMO4, CES1, UGT2B4, and UGT2B7 expression. The differential sensitivity persisted at enzyme activity level, highlighting that alterations in DME gene expression during inflammation are predictive for subsequent alterations in enzyme activity. In conclusion, this study has shown that FMOs, CESs, and UGTs enzymes are less impacted by IL-6 and IL-1 β treatment as compared with CYP enzymes.

Significance statement

While the impact of proinflammatory cytokines on CYP expression is well established, their effects on non-CYP phase I and phase II drug metabolism remains underexplored, particularly regarding alterations in drug metabolizing enzyme (DME) activity. This study provides a quantitative understanding of the sensitivity differences to inflammation between DME family members, suggesting that non-CYP DMEs may become more important for the metabolism of drugs during inflammatory conditions due to their lower sensitivity as compared with the CYPs.

Introduction

Inflammation is increasingly recognized as a contributor to the regulation and variability of drug clearance in humans, presumably due to alterations in drug metabolism (1,2). More specifically, the widespread elevation of proinflammatory cytokines, such as interleukin (IL)-6 and IL-1 β affects gene expression of drug metabolizing enzymes (DMEs) in hepatocytes (3–7), subsequently affecting hepatic drug clearance and efficacy or safety of drug treatments (8). Considering the high prevalence of both acute and chronic inflammatory diseases, it is crucial to take into account how hepatic drug metabolism of both novel and existing drugs can be affected by inflammation.

In vitro studies using human liver models have been instrumental in broadening our understanding of inflammation-induced alterations in drug metabolism and can facilitate in quantifying these effects. A promising approach to predict the subsequent impact of inflammation on drug clearance in vivo involves utilizing in vitro data coupled with physiologically based pharmacokinetic (PBPK) models. This approach has demonstrated its utility in predicting the influence of elevated IL-6 levels on drug clearance, particularly for substrates of the key DMEs cytochrome P450 (CYP) 3A4 and CYP2C19 (9–13). Generating more physiologically relevant quantitative in vitro data will likely aid in utilizing PBPK models to predict the impact of inflammation on drug clearance for substrates of other CYP enzymes and non-CYP mediated pathways (14).

Importantly, it is estimated that clearance of ~25% of the top 200 most prescribed small molecule drugs approved by the FDA is mainly dependent on non-CYP enzymes, with the UDP-glucuronosyltransferase (UGT) family contributing to biotransformation in 45% of the cases (15). However, whereas the impact of proinflammatory cytokines on CYP expression is well established, the potential impact on other DME families, including the UGTs, sulfotransferases, flavin-containing monooxygenases (FMOs), and carboxylesterases (CESs), has received considerably less attention. Yet, it remains unclear to what extent the activity of non-CYP metabolizing enzymes is affected by inflammation, and whether these enzymes exhibit a comparable sensitivity to the effects of inflammatory cytokines as compared with the CYP enzymes.

Another limitation of available in vitro data is that they have mostly focused on the impact of cytokines on the mRNA expression levels of DME enzymes rather

than on their enzymatic activity. While significant changes in the expression of DME mRNA during inflammation have indeed prompted focus on transcription as the primary mechanism underlying changes in metabolic capacity, there is increasing acknowledgment of the influence of post-transcriptional mechanisms on DME activity (1). Consequently, a strong up- or downregulation of mRNA expression observed upon cytokine stimulation may not necessarily translate into similar alterations in enzyme activity. Furthermore, in vitro studies are often conducted using cytokine concentrations that surpass the physiological concentrations observed in patients, compromising clinical translation (16). IL-6 levels typically range from 10 to 1000 pg/ml during inflammatory conditions, and IL-1 β can reach up to 50 pg/ml (11,17,18). However, most in vitro studies have exclusively examined the effects of 10 ng/ml IL-6 and 1 ng/ml IL-1 β , concentrations that far exceed physiological levels. This underscores the necessity of investigating changes in enzymatic activity upon physiologically relevant concentrations of cytokines to generate reliable quantitative in vitro data.

In this study, we therefore investigated the concentration-dependent effects of IL-6 and IL-1 β on both the mRNA expression and activity of CYP and non-CYP DMEs in a relevant human hepatocarcinoma cell line, i.e., in HepaRG cells. Quantifying the impact of inflammatory mediators across various DME families allowed us to establish a hierarchy of their sensitivity. By comparing the effects of IL-6 and IL-1 β on transcription versus activity, we shed light on whether alterations in mRNA serve as a reliable predictor of corresponding changes in enzyme activity during inflammation. This information is essential for enhancing our understanding of the impact of inflammation on drug metabolism, and could be implemented in modeling tools aimed at optimizing drug dosing strategies for patients with inflammatory disease.

Materials and methods

Reagents and chemicals

William's E Medium with GlutaMAX Supplement and trypsin-EDTA (0.25%) were purchased from ThermoFisher (Waltham, MA, USA). Fetal bovine serum was obtained from Merck (Batch number: 0001663799), penicillin/streptomycin was obtained from Lonza (Basel, Switzerland). Hydrocortisone, DMSO, human

insulin, and primers were obtained from Sigma-Aldrich (St. Louis, Missouri, USA). Dulbecco's phosphate-buffered saline (PBS) was obtained from Capricorn Scientific (Ebsdorfergrund, Hessen, Germany). SensiMix SYBR Lo-ROX kit and 10x NH4 Reaction Buffer for reverse transcription-quantitative polymerase chain reaction (RT-qPCR) were purchased from Meridian BioScience (Cincinnati, Ohio, USA). Maxima H minus Reverse transcriptase and 5x RT buffer was purchased from Thermo Scientific (Waltham, MA, USA). Human recombinant IL-6 and human recombinant IL-1 β were purchased from Peprotech (London, UK). All cytokines were reconstituted and stored as high concentration stocks according to the manufacturer's instructions. S-mephenytoin, 4'-hydroxymephenytoin, 4'-hydroxymephenytoin-d₃, diclofenac, 4'-hydroxydiclofac, 4'-hydroxydiclofenac-¹³C₆, phenacetin, acetaminophen, benzydamine N-oxide, and benzydamine N-oxide-d₆ were purchased from LGC (Wesel, Germany). Acetaminophen-d₄ was purchased from Alsachim (Illkirch-Graffenstaden, France). Benzydamine was purchased from Sigma-Aldrich (St. Louis, MO, USA). 1'-Hydroxymidazolam was purchased from Cerilliant (Round Rock, Texas, USA) and 1'-hydroxymidazolam-d₄ from Supelco (St. Louis, Missouri, USA). Midazolam hydrochloride, morphine, morphine-3-glucuronide, and morphine-3-gluronide-d₃ were from Duchefa Farma (Haarlem, the Netherlands). Acetonitrile, methanol, water, and formic acid of LC-MS grade were obtained from Merk (Darmstadt, Germany).

HepaRG culture and treatment

HepaRG cells at passage 12 (batch HPR101067) were purchased from Biopredict International (Rennes, France) and expanded to set up a working bank according to the provider's instructions. Cells plated in 96-wells plates at a density of 9000 cells/well were first grown in William's E medium GlutaMAX supplemented with 10% fetal bovine serum, 100 U/ml penicillin/streptomycin, 5 μ g/ml human insulin, and 20 μ g/ml hydrocortisone for two weeks. Subsequently, cells were cultured for an additional two weeks in the same medium supplemented with 2% DMSO to get fully differentiated cells (19). Cells were maintained at 37°C in 5% CO₂ throughout the experiment.

The fetal bovine serum concentration in the DMSO-containing HepaRG medium was reduced to 1% at 24 hours before treatment with the cytokines IL-6 or IL-1 β . Concentrations of IL-6 used for the experiments ranged from 0.0001

ng/ml to 10 ng/ml and from 0.001 pg/ml to 1 ng/ml for IL-1 β , respectively. For gene expression analysis, cells were treated with IL-6 or IL-1 β for 24 hours prior to lysis. For activity measurements, the cytokine-containing medium was renewed every 24 hours. After 72 hours, the medium was replaced by 2% DMSO-containing serum-free medium with a substrate specific to the DME of interest, as described in detail below. An CyQUANT LDH Cytotoxicity Assay (Thermo Scientific, Wilmington, US) was conducted after 72 hours to evaluate cytotoxicity at the highest concentrations of IL-6 and IL-1 β , yielding cytotoxicity levels of 6% and 14%, respectively.

Human liver biopsies

Human liver biopsies were obtained from the gastroenterology biobank at the Leiden University Medical Center (LUMC, Leiden, the Netherlands), as described elsewhere (20).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA was isolated from HepaRG cells or human liver biopsies following the acid guanidinium thiocyanate-phenol-chloroform extraction, as described elsewhere (21). Concentration and purity of RNA was subsequently measured using a NanoDrop 3300 (Thermo Scientific, Wilmington, US). Synthesis of cDNA was performed with 0.5 μ g RNA input using Maxima H Minus Reverse Transcriptase (Thermo scientific) according to the manufacturer's instructions. RT-qPCR analysis was performed with a QuantStudio 6 Flex System using SYBR Green technology. RT-qPCR samples were run in duplicate. All PCR primers were designed in-house and subsequently checked for amplification efficiency (Supplemental Table 1). Relative mRNA levels were calculated using the comparative $\Delta\Delta C_t$ method (22). The expression in each HepaRG sample was normalized by subtracting the geometric mean C_t value of the endogenous control genes ribosomal protein lateral stalk subunit P0 (RPLP0), glyceraldehyde-3-phosphate dehydrogenase and β -actin (ACTB) from the target C_t value to obtain the ΔC_t (eq. 1).

$$\Delta C_t = C_t(target) - C_t(RPLP0, GAPDH, ACTB) \quad (1)$$

Subsequent relative gene expression levels were calculated as $2^{-\Delta C_t}$. Fold changes of treated cells as compared to PBS-control cells were calculated using eq. 2 and 3.

$$\Delta\Delta Ct = \Delta Ct(treated) - \Delta Ct(PBS\ control) \quad (2)$$

$$Fold\ change = 2^{-\Delta\Delta Ct} \quad (3)$$

Data are expressed as mean fold changes $\pm$ S.E.M. Basal gene expression in HepaRG cells and human liver biopsies presented in Figure 1 and Supplemental Figure 2 are exclusively normalized for *RPLP0*. This is due to the fact that *RPLP0* was identified as a stable endogenous control in liver biopsies, unlike other housekeeping genes (20). Statistical analyses were carried out on ΔCt values due to the considerably skewed symmetry of up- and downregulation in the linear fold change.

DME activities in HepaRG cells

Determination of DME activity was based on the metabolic conversion of probe substrates, i.e., midazolam for CYP3A4, phenacetin for CYP1A2, diclofenac for CYP2C9, S-mephenytoin for CYP2C19, benzydamine for FMO3, and morphine for UGT2B7 using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). CYP2D6 activity could not be determined since HepaRG cells are derived from a CYP2D6 poor metabolizer patient and was thus excluded from our analysis (23). Cells were exposed to 5 μ M midazolam for 30 minutes, 50 μ M phenacetin for 2 hours, 10 μ M diclofenac for 2 hours, 100 μ M S-mephenytoin for 2 hours, 10 μ M benzydamine for 4 hours, or 100 μ M morphine for 4 hours in serum-free William's E medium supplemented with 2% DMSO. Substrate concentrations were selected below the Michaelis-Menten constant to achieve selective metabolic conversion by the specific DME isoform (24–26). Afterward, cell medium samples containing the probe substrates and their metabolites were collected and mixed with 250 mM formic acid, and immediately frozen at -20 degrees. Notably, UGT2B7 activity samples were mixed with 1 M sodium carbonate and then frozen. For quantification of the metabolites 1'hydroxymidazolam (CYP3A4), acetaminophen (CYP1A2), 4'hydroxydiclofenac (CYP2C9), 4'hydroxymephenytoin (CYP2C19), benzydamine-N-oxide (FMO3), or morphine-3-glucuronide (UGT2B7) samples were subjected to LC-MS/MS based analysis. A detailed description of the LC-MS/MS analysis can be found in the Supplemental Methods 'LC-MS/MS method to quantify CYP activity' or 'LC-MS/MS method to quantify FMO3 and UGT2B7 activity', where MS-specific parameters are listed in Supplemental Tables 2 and 3. CES1 activity was not determined due to the absence of a probe-based analytical

detection method. Enzyme activity data were normalized to the amount of cells per well and presented as the rate of metabolite formation in picomole/min/million cells as compared with untreated cells.

Statistical analysis

Results were generated from at least four independent experiments. Relative IC_{50} of IL-6 and IL-1 β for DME expression and activity were determined using GraphPad Prism 9.2.0 software (GraphPad Software, La Jolla, CA, USA) through nonlinear regression on the basis of the four-parameter logistic function (27). In case the concentration-response curve did not reach the lower asymptote upon the highest cytokine stimulation, IC_{50} values were determined by directly interpolating from the studied concentration-response curve, without extrapolation for higher cytokine concentrations beyond the range of observed data points. Percentual maximal inhibition (I_{max}) values were calculated based upon the upper and lower asymptotes of the concentration-response curves. Statistical significance in IC_{50} and I_{max} values between DME isoforms was determined by the parametric one-way ANOVA test assuming normal distribution of data and applying the Dunnett's post hoc test for comparison with CYP3A4 in GraphPad Prism 9. Statistical significance between IC_{50} and I_{max} values on mRNA and activity was done using an unpaired t test. The criterion was based on the p -values and indicated with * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$ and NS, not significant.

Results

Basal mRNA expression of DMEs in HepaRG is comparable to human livers

The mRNA expression levels of four CYP enzymes (CYP3A4, CYP2C9, CYP2C19, CYP1A2), five other phase I enzymes (FMO1, FMO3, FMO4, CES1, CES2), and four phase II enzymes (UGT1A4, UGT2B4, UGT2B7 and UGT2B15) were analyzed by RT-qPCR in HepaRG cells and biopsies of human livers (Figure 1). Rank order of P450 expression was CYP3A4 > CYP2C9 > CYP2C19 > CYP1A2 in HepaRG cells and CYP2C9 > CYP3A4 > CYP2C19 > CYP1A2 in human livers. CYP1A2 expression was relatively low in HepaRG as compared with human livers, consistent with previous characterization studies (23). The rank order of other phase I enzymes expression was FMO3 > FMO4 > FMO1

and *CES1* > *CES2*. For the included phase II enzymes, the expression order was UGT2B4 > UGT2B15 > UGT1A4 > UGT2B7. This pattern was consistent in both HepaRG cells and human livers, aligning with previous research (28,29). Thus, the rank order within DME families exhibited strong similarity between human livers and the HepaRG cell model, suggesting that the HepaRG cell model is not only suitable for providing translation input regarding CYP enzymes but also for other DME families.




Figure 1 Basal mRNA expression levels of phase I and phase II drug metabolizing enzymes in HepaRG cells and in human livers. mRNA expression of the gene of interest was normalized to the housekeeping gene RPLP0 and presented as a fold change compared to basal CYP3A4 expression of either HepaRG cells or human livers. All values are means + SEM from 8 independent experiments (HepaRG) or from biopsies of 40 human livers.

Impact of proinflammatory cytokine treatment on CYP expression and activity

The effect of inflammation on the gene expression and enzyme activity of selected phase I and phase II DMEs was evaluated by determining the IC_{50} (potency) and I_{max} (efficacy) values of IL-6 and IL-1 β on individual isoforms.

A concentration-dependent decrease in the relative mRNA expression of all CYP isoforms was observed following treatment with both IL-6 and IL-1 β . Among the CYP family members, no substantial differences were noted in the isoform-specific response to cytokine treatment, as evident from the comparable potency and efficacy values (Figure 2A, Table 1). Comparison of IC_{50} values and maximum suppression values for IL-1 β and IL-6 indicated that in general, IL-1 β is much more

potent than IL-6 in suppressing DME gene expression and enzyme activity. This finding corroborates previous research in HepaRG cells (7). We next examined whether the alterations at the DME gene expression level were retained at the enzyme activity level. Indeed, a concentration-dependent decrease was observed for CYP activity of all isoforms (Figure 2B, Table 2). In contrast to the similar potencies of IL-6 and IL-1 β in modulating expression levels of different CYP isoforms, there was a distinct potency difference (~10-fold) between the impact of inflammation on CYP2C19 and CYP2C9 enzyme activities as compared with CYP3A4 activity, which was reflected by a higher sensitivity of CYP3A4 activity toward IL-6 and IL-1 β .




Figure 2 Cytokine concentration-response curves for regulation of CYP isoforms CYP3A4, CYP2C9, CYP2C19, CYP1A2 on expression (A) and activity level (B). Cells were treated with concentrations of 0.0001 ng/mL to 10 ng/mL (IL-6) or 0.001 pg/mL to 1 ng/mL (IL-1 β) for 24 hours to analyze gene expression alterations via RT-qPCR or for 72 hours to analyze activity alterations via probe substrate metabolism with LC-MS/MS. mRNA and activity data are expressed as fold change of levels found in untreated control cells, arbitrarily set to 1.0. Each data point represents the average $\pm$ SEM of at least 4 independent experiments. Data were fit with a non-linear regression model.

Table 1 Quantified IC_{50} and I_{max} values for DME mRNA expression levels obtained from fitting a non-linear regression model on the concentration-effect curves after treatment with IL-6 or IL-1 β for 24 hours. The IC_{50} values are reported in ng/mL for IL-6 treatment and in pg/mL for IL-1 β treatment. One-way ANOVA and Dunnett's post hoc test with comparison to CYP3A4 was done to investigate differences in potency and maximal effect between DME families, for both IL-6 and IL-1 β treatment. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

	IL-6		IL-1 β	
	Potency (IC_{50} , ng/mL) $\pm$ SD	Maximal effect (I_{max}) $\pm$ SD (%)	Potency (IC_{50} , pg/mL) $\pm$ SD	Maximal effect (I_{max}) $\pm$ SD (%)
CYP3A4	0.14 $\pm$ 0.10	97 $\pm$ 1	0.35 $\pm$ 0.94	99 $\pm$ 2
CYP1A2	0.04 $\pm$ 0.22	94 $\pm$ 3	0.24 $\pm$ 1.02	99 $\pm$ 1
CYP2C9	0.41 $\pm$ 0.29	82 $\pm$ 6	0.90 $\pm$ 2.05	94 $\pm$ 4
CYP2C19	0.27 $\pm$ 0.47	86 $\pm$ 5	0.98 $\pm$ 1.23	94 $\pm$ 6
FMO1	0.57 $\pm$ 0.22	84 $\pm$ 11	1.80 $\pm$ 4.47	97 $\pm$ 3
FMO3	1.00 $\pm$ 1.86**	55 $\pm$ 9***	6.15 $\pm$ 12.10**	84 $\pm$ 6**
FMO4	1.07 $\pm$ 0.95**	57 $\pm$ 4***	9.95 $\pm$ 13.56***	80 $\pm$ 3***
CES1	1.23 $\pm$ 0.30**	39 $\pm$ 15***	no effect	no effect
CES2	0.70 $\pm$ 0.30*	48 $\pm$ 13***	10.67 $\pm$ 9.32**	84 $\pm$ 1*
UGT1A4	0.61 $\pm$ 0.88*	68 $\pm$ 17***	1.93 $\pm$ 7.63	84 $\pm$ 17**
UGT2B4	0.76 $\pm$ 0.58*	73 $\pm$ 7***	3.28 $\pm$ 14.19*	94 $\pm$ 4
UGT2B7	1.05 $\pm$ 0.42 **	60 $\pm$ 12***	5.01 $\pm$ 17.97**	83 $\pm$ 10***
UGT2B15	0.59 $\pm$ 0.30	72 $\pm$ 13***	1.53 $\pm$ 6.55	97 $\pm$ 2

Table 2 Quantified IC_{50} and I_{max} values for DME activity obtained from fitting a non-linear regression model on the concentration-effect curves after treatment with IL-6 or IL-1 β for 72 hours. The IC_{50} values are reported in ng/mL for IL-6 treatment and in pg/mL for IL-1 β treatment. One-way ANOVA and Dunnett's post hoc test with comparison to CYP3A4 was done to investigate differences in potency and efficacy between DME families, for both IL-6 and IL-1 β . * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

	IL-6		IL-1 β	
	Potency (IC_{50} , ng/mL) $\pm$ SD	Maximal decrease (I_{max}) $\pm$ SD (%)	Potency (IC_{50} , pg/mL) $\pm$ SD	Maximal decrease (I_{max}) $\pm$ SD (%)
CYP3A4	0.05 $\pm$ 0.17	93 $\pm$ 2	0.60 $\pm$ 2.31	98 $\pm$ 1
CYP1A2	0.12 $\pm$ 0.11	85 $\pm$ 4*	0.43 $\pm$ 3.55	89 $\pm$ 1***
CYP2C9	0.55 $\pm$ 0.36***	89 $\pm$ 3	4.82 $\pm$ 4.59*	93 $\pm$ 3**
CYP2C19	0.52 $\pm$ 0.17***	89 $\pm$ 2	6.58 $\pm$ 6.27*	99 $\pm$ 0
FMO3	1.28 $\pm$ 1.82***	29 $\pm$ 5***	1.49 $\pm$ 0.43	54 $\pm$ 5***
UGT2B7	1.77 $\pm$ 0.71***	69 $\pm$ 7***	18.48 $\pm$ 15.54**	93 $\pm$ 2*

Non-CYP isoforms are differentially affected by cytokine treatment as compared with CYP isoforms

We next examined the impact of IL-6 and IL-1 β treatment on the different members of the most important non-CYP DME families. Sensitivity differences in response to cytokine treatment among DME families were defined by benchmarking potency and efficacy values against CYP3A4, which is recognized as the most important DME in humans because of its clinical importance and high expression (30). Interestingly, gene expression of *FMO3*, *FMO4*, *CES1*, *CES2*, *UGT1A4*, *UGT2B4*, and *UGT2B7* was in terms of potency less sensitive toward the effects of IL-6 as compared with CYP3A4, with IC₅₀ values that were 4- to 9-fold higher than for CYP3A4 (Figure 3A, Table 1). Additionally, while IL-6 elicited a maximal downregulation of only 55 $\pm$ 9% for *FMO3*, 57 $\pm$ 4% for *FMO4*, 39 $\pm$ 15% for *CES1*, and 48 $\pm$ 13% for *CES2*, it led to a nearly complete downregulation of 97 $\pm$ 1% for CYP3A4 expression. This difference in efficacy of IL-6 was similarly observed across all members of the *UGT* family, where maximal downregulation ranged from 60 $\pm$ 12% to 73 $\pm$ 7%.

Similar patterns were observed for the impact of IL-1 β on non-CYP DME isoforms. *FMO3*, *FMO4*, *CES2*, *UGT2B4*, and *UGT2B7* exhibited a significantly lower sensitivity to IL-1 β as compared with CYP3A4, indicating that a, respectively, 18-, 28-, 30-, 9-, and 14-fold higher concentration of IL-1 β was needed to exert 50% of the maximal downregulation by this cytokine. Interestingly, IL-1 β did not impact *CES1* expression across all concentrations tested. In addition, the maximal inhibitory effect of IL-1 β on gene expression levels of *FMO3*, *FMO4*, *CES2*, *UGT1A4*, and *UGT2B7* ranged from 80 $\pm$ 3% to 84 $\pm$ 17%, which was less as compared with the observed near-complete downregulation of 99 $\pm$ 2% of CYP3A4.

Importantly, the differential potency and maximal inhibitory impact of inflammatory mediators on different members of the DME families could be confirmed at the enzyme activity level (Figure 3B, Table 2). Compared with CYP3A4 activity, *FMO3* activity was less sensitive toward the effects of IL-6, as evident by a 26-fold difference in potency. *UGT2B7* activity was even less sensitive toward IL-6, with a 35-fold difference in IC₅₀ value as compared with CYP3A4 activity. In addition, maximal inhibition by IL-6 was only 29 $\pm$ 5% for *FMO3*, and 69 $\pm$ 7% for *UGT2B7*, significantly less than the maximal inhibition of 93 $\pm$ 2% that was observed for CYP3A4 activity. The maximal downregulation of *FMO3* activity following IL-1 β treatment was 54 $\pm$ 5%, which was also less than observed

for the CYP3A4 activity ($98 \pm 1\%$). However, IL- 1β showed comparable potency toward FMO3 activity inhibition as compared with CYP3A4 activity inhibition, highlighting that the efficacy of IL- 1β rather than the sensitivity to IL- 1β differed between FMO3 and CYP3A4 activities. UGT2B7 activity displayed lower sensitivity toward IL- 1β , which was reflected by a 31-fold difference in IC_{50} value as compared with CYP3A4.




Figure 3 Cytokine concentration-response curves for regulation of CYP3A4, FMO3, UGT2B7 and CES1 on expression (A) and activity level (B). Cells were treated with concentrations of 0.0001 ng/mL to 10 ng/mL (IL-6) or 0.001 pg/mL to 1 ng/mL (IL- 1β) for 24 hours to analyze gene expression alterations via RT-qPCR or for 72 hours to analyze activity alterations via probe substrate metabolism with LC-MS/MS. mRNA and activity data are expressed as fold changes of levels found in untreated control cells, arbitrarily set to 1.0. Each data point represents the average $\pm$ SEM of at least 4 independent experiments. Data were fit with a non-linear regression model.

Transcriptional regulation is the main driver of the cytokine-mediated inhibition of DMEs

Several studies have suggested that inflammation-related post-transcriptional mechanisms may modulate CYP activity, which would theoretically result in a mismatch in the overall impact of inflammatory mediators in altering DME gene

expression versus enzyme activity. To investigate whether post-transcriptional modifications induced by inflammation are indeed critical to the effect, acquired IC_{50} and I_{max} values for DME gene expression and enzyme activity were compared (Figure 4). Overall, there was a strong linear relationship between the potency of IL-6 and IL-1 β on DME expression and DME activity ($p < 0.0001$) (Figure 4A). Importantly, 90% of the variability in DME activity could be explained by changes in transcription ($R^2 = 0.9$), highlighting the strong association between alterations in gene expression and enzyme activity during inflammation. We next compared individual expression versus activity IC_{50} values for CYP3A4, CYP2C19, CYP2C9, CYP1A2, FMO3, and UGT2B7, visually presented in Supplemental Figure 1. CYP3A4 activity was more sensitive toward IL-6 induced downregulation compared with CYP3A4 expression, and this was similarly seen for FMO3 activity upon IL-1 β treatment. In contrast, CYP2C19 and CYP2C9 expression was more sensitive toward IL-1 β treatment as compared with CYP2C19 and CYP2C9 activity. For other isoforms, similar IC_{50} values on expression and activity level were found. The maximal impact of IL-6 and IL-1 β on expression and activity of the DMEs was highly similar, except for the mismatches observed for FMO3 (Figure 4B).




Figure 4 Simple linear regression analysis to investigate the relationship between the impact of IL-6 and IL-1 β treatment on DME mRNA expression versus activity for $LogIC_{50}$ values (A) and I_{max} values (B). The regression line represents the best-fit line calculated from the data, and the dotted lines indicate the 95% confidence interval. Blue dots represent data obtained from IL-6 treated cells, and brown dots represent data obtained from IL-1 β treated cells.

Comparison of IC₅₀ values for cytokine-induced CYP changes in HepaRG cells versus two-dimensional (2D) and three-dimensional (3D) primary human hepatocyte (PHH) models

To further highlight the translational value of the HepaRG cell line as in vitro liver model, we compared our quantitative cytokine-induced changes to what has been reported before in 2D and 3D PHH models (4,5,31). Comparing our HepaRG IL-6 IC₅₀ values with those previously determined for CYP isoforms in 2D/3D PHHs showed good agreement between the results (Table 3). The potency of IL-6 in inducing transcriptional alterations in CYPs in 3D PHH spheroids was almost identical as compared with the potency found in HepaRG cells. The IC₅₀ data acquired in a 2D PHH model were also comparable. However, it should be noted that basal CYP expression rapidly declines in 2D cultures of PHH, even in the absence of a proinflammatory stimulus (32). The correspondence of our HepaRG IC₅₀ data does not hold so well for comparing the potency of IL-1 β on CYP expression and activity in PHHs. Although we found the most pronounced effects on CYP3A4, similarly to the results in 3D PHHs, IL-1 β was much more potent in HepaRG cells as compared with PHHs. This might in part be due to the morphological heterogeneity of HepaRG cells, where biliary-like cells release additional proinflammatory cytokines, amplifying the IL-1 β response (33). Indeed, aggravation of the IL-1 β , but not the IL-6 response has been demonstrated in hepatocyte coculture models as compared with hepatocytes alone, where a sensitivity increase up to 50-fold was observed for CYP3A4 (34). Taken together, these findings demonstrate that HepaRG cells exhibit comparable sensitivity to IL-6-induced transcriptional changes in CYP enzymes as observed in 2D and 3D PHH models.

Cytokine specific effects on nuclear receptors and transcription factors regulating the DMEs

Our data indicates that transcriptional alterations in DME are the primary mechanism underlying inflammation-related changes in CYP enzyme activity in vitro. To gain mechanistic insight into the differential regulation of hepatic gene expression by cytokines, we investigated the effects of IL-6 and IL-1 β on a selection of nuclear receptors and transcription factors generally considered to be involved in DME gene expression regulation (Figure 5).

Table 3 Quantified IC₅₀ values in HepaRG cells from this study as compared to reported values in 2D and 3D PHH models. Data from 3D PHH models was extracted from the publication by Klöditz et al. (2023) and represents the average of 4 independent donors. Data from 2D PHHs was extracted from the studies by Dickmann et al. (2011, 2012) and represents the average of 5 independent donors unless stated otherwise.

	IL-6					IL-1β				
	HepaRG (IC ₅₀ , ng/mL)		3D PHH (IC ₅₀ , ng/mL)		2D PHH (IC ₅₀ , ng/mL)	HepaRG (IC ₅₀ , ng/mL)		3D PHH (IC ₅₀ , ng/mL)		2D PHH (IC ₅₀ , ng/mL)
	mRNA	Activity	mRNA	Activity	mRNA [#]	mRNA	Activity	mRNA	Activity	mRNA
CYP3A4	0.14	0.05	0.46	N.D.	0.003	0.0004	0.0006	0.02	N.D.	0.29
CYP1A2	0.04	0.12	0.03	N.D.	0.27	0.0002	0.0004	0.60	N.D.	0.53 ^{###}
CYP2C9	0.41	0.55	0.20	N.D.	0.12	0.0009	0.0048	3.95	N.D.	0.23
CYP2C19	0.27	0.52	0.25	N.D.	0.07	0.0010	0.0066	0.42	N.D.	0.15 ^{###}

N.D. = not determined. [#] data from one donor; [#] could only be measured in 2 out of 5 donors; ^{###} could only be measured in 3 out of 5 donors.




Figure 5 The impact of IL-6 or IL-1 β on transcription factors and nuclear receptors that regulate the various DMEs families. Cells were treated with 10 ng/mL IL-6 or 1 ng/mL IL-1 β for 24 hours to analyze gene expression alterations via RT-qPCR. Data are expressed as the mean fold change $\pm$ SEM of mRNA compared to untreated control cells of 6 independent experiments. One way ANOVA with Dunnett post hoc test was performed for every gene separately. ** $p < 0.01$; *** $p < 0.001$.

Pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are identified as key transcriptional regulators of the CYP enzymes, with confirmed binding sites in the response elements of human CYP3A4/5, CYP2C9, CYP2C19, and CYP1A2 (35–37). Nuclear factor Y (NFY) and upstream transcription factor 1 (USF1) are essential for constitutive FMO3 transcription via promoter binding (38), while liver X receptor α (LXR α) has recently been identified as regulator of human CES (39). UGT family regulation is isoform-specific, with the aryl hydrocarbon receptor (AhR) and hepatocyte nuclear factor (HNF) 1 α implicated in UGT1A4 regulation, farnesoid X receptor (FXR) and peroxisome proliferator activated receptor α (PPAR α) in UGT2B4 regulation, and nuclear factor E2-related factor 2 (Nrf2), FXR, HNF4 α , HNF1, vitamin D receptor (VDR), and forkhead box protein A1 (FOXA1) in the regulation of UGT2B7 and UGT2B15 (40). Basal gene expression of these regulators in HepaRG cells was confirmed with RT-qPCR (Supplemental Figure 2). PXR and CAR expression was most strongly downregulated, i.e., > 60% by IL-6 treatment and > 90% by IL-1 β treatment. IL-1 β also downregulated PXR and CAR's binding partner retinoid X receptor α (RXR α) (~60%), LXR α (~80%), HNF1 α (~80%), AhR (~50%), Nrf2 (~70%), and PPAR α (~80%), which was not seen after IL-6 treatment. Expression of HNF4 α was downregulated by ~70% following IL-1 β treatment and ~40% by IL-6

treatment. The other regulators FXR, NFY, and USF1 were unaffected by both IL-6 and IL-1 β . Sensitivity toward IL-6 and IL-1 β was evaluated for PXR and CAR, as these regulators were most affected by cytokine treatment. The IC₅₀ values for IL-6 treatment were 0.86 ± 0.46 ng/ml for PXR and 0.38 ± 0.56 ng/ml for CAR, while for IL-1 β treatment, the IC₅₀ values were 4.37 ± 3.68 pg/ml for PXR and 2.50 ± 7.41 pg/ml for CAR. Concentration-response curves for PXR and CAR as compared with one of the key genes they regulate, *CYP3A4*, is presented in Supplemental Figure 3.

Discussion

Proinflammatory cytokine release during inflammatory conditions is associated with compromised metabolism of drugs in the liver. The impact of proinflammatory cytokines on in vitro CYP expression is well-characterized (16). However, less attention has been credited to the effects on non-CYP phase I and phase II drug metabolism, and especially data on the effects of inflammation on DME activity is lacking. Our results demonstrate that members of the non-CYP families FMOs, CESs, and UGTs were less sensitive toward the effects of IL-6 and IL-1 β as compared with the CYP family. This differential sensitivity was evident at both the DME gene expression and DME enzyme activity level, highlighting that alterations in transcription during inflammation are highly predictive for subsequent alterations in enzyme activity.

Our concentration-response experiments defined differences in both the potency and efficacy of cytokines in inducing downregulation of expression and activity of individual DME family members. While results from previous in vitro studies at supraphysiological concentrations of IL-6 have hinted toward a more limited impact on UGT isoforms as compared with CYP isoforms (7,41,42), this study is the first to directly compare multiple DME families on both expression and activity. Rank ordering of DME sensitivity highlighted that CYP isoforms exhibited the highest sensitivity to the modulatory effects of IL-6 and IL-1 β , whereas members from the FMO, CES, and UGT families consistently showed a lower sensitivity. Importantly, this differential sensitivity was observed for both IL-6 and IL-1 β treatment, even though IL-6 and IL-1 β induce different inflammatory signaling pathways (43,44) and exert different effects on transcriptional regulators (7).

The mechanisms underlying this differential sensitivity could stem from the differential impact of cytokines on the regulators of the DMEs. IL-6 and IL-1 β stimulation of HepaRG cells profoundly and significantly suppress mRNA expression of PXR and CAR by > 60%, whereas presumed transcriptional regulators of UGT and CES enzymes are less impacted, and FMO regulators are not at all impacted by cytokine treatment. Nuclear receptors and transcription factors implicated in DME transcriptional modulation are thus transcriptionally differentially regulated by cytokines, which might underlie the differential sensitivity to inflammation observed for various DME families. In addition to inflammation-induced alterations in gene expression of regulators, a loss of nuclear localization or alterations in the phosphorylation status of regulators has also been proposed, i.e., for the dimerization partner RXR α (41,45). This might explain the observed mismatch between the sensitivity toward proinflammatory cytokines for CYP3A4 expression as compared with expression of the key regulators PXR and CAR. Future studies should aim to investigate whether the transcriptional downregulation concordantly leads to lower transcriptional activation of DME regulators.

Post-transcriptional mechanism related to inflammation may, alongside transcriptional changes, further affect CYP activity (1). For instance, nitric oxide-dependent ubiquitination leading to enhanced proteasomal degradation, or the release of inflammation-related miRNAs, have been implicated in this post-transcriptional regulatory process (46–48). To investigate the importance of post-transcriptional mechanisms in modulating CYP activity under inflammatory conditions, we analyzed the correlation between the impact of IL-6 and IL-1 β on DME expression versus DME activity. We found that, in HepaRG cells, alterations in gene expression are highly predictive for alterations in enzyme activity, providing limited evidence for inflammation-associated post-transcriptional modifications of DMEs. Previous studies suggesting the importance of post-transcriptional modifications on CYP activity mainly stem from observed mismatches between mRNA and protein levels in PHHs (49) or from animal studies (1). The time kinetics of alterations in expression versus protein/activity levels could partially account for the observed mismatches, and future studies should therefore evaluate the temporal dynamics of DME expression and activity alterations in response to inflammation. We conducted our activity measurements after 72 hours, in accordance with other studies and considering the reported half-life of CYP3A4,

which is approximately 37 hours (50). However, half-life of CYP2C9 is reported to be 104 hours (50), which could explain why we found a stronger effect of inflammation on *CYP2C9* expression compared with its activity. This finding is thus likely unrelated to post-transcriptional modifications but rather an effect of the protein's half-life. All in all, our results have highlighted that the transcriptional alterations in DME expression are the main driver of the alterations in enzyme activity observed in vitro.

PBPK modeling is increasingly exploited to predict the impact of inflammation or inflammatory diseases on drug clearance. A major advantage of PBPK modeling combined with in vitro to in vivo extrapolation (IVIVE) is the ability to translate in vitro data into biologically relevant parameters for model input to predict clinical inflammation-related alterations in pharmacokinetics. Specifically, IC_{50} and I_{max} values obtained in vitro can be used to model CYP enzyme dynamics under inflammatory conditions, and this approach has been shown successful for the prediction of disease–drug interactions with CYP substrates in, for example, patients with rheumatoid arthritis, leukemia, or surgical trauma (9,11–13,51). Despite the growing interest in PBPK modeling for non-CYP enzymes, current models predominantly focus on predicting drug–drug interactions rather than the impact of inflammation on non-CYP mediated drug clearance (14). This limitation arises partly due to the scarcity of physiologically relevant quantitative in vitro data on the effects of cytokines on non-CYP enzymes (52,53). To address this gap, we provided IC_{50} and I_{max} values for non-CYP enzymes, which can serve as critical inputs for PBPK modeling to better predict inflammation-related changes in non-CYP mediated drug metabolism. Importantly, comparing our HepaRG IL-6 IC_{50} values with those previously determined for CYP isoforms in 2D/3D PHHs showed good agreement between the results, enhancing our confidence in the validity of HepaRG data as input for PBPK modeling approaches. Also, our reported IC_{50} data are within the physiological range of serum IL-1 β and IL-6 in patients experiencing inflammation-related diseases (17). Ultimately, PBPK models, when integrated with robust in vitro data, could serve as a powerful tool for optimizing drug dosing strategies and enhancing therapeutic outcomes in the presence of inflammation.

In the clinic, a differential impact of inflammation on DME family members has been observed, for example in nonalcoholic fatty liver disease (NAFLD) patients,

where hepatic inflammation is an important contributor to disease progression (54). Protein levels of CYPs were lower in diseased patients, but non-CYP enzyme levels remained relatively unchanged, except for select UGTs (55). This was confirmed in other studies which showed CYP2C19 to be most impacted by NAFLD, whereas other DMEs were less affected (56,57). For antifungal agents, a differential impact of inflammation has been demonstrated based on the metabolic route of the drug. Exposure of posaconazole, which is mainly metabolized by UGT1A4, was not influenced by inflammation as assessed by C-reactive protein (CRP) levels (58). Conversely, different studies have demonstrated that trough levels of voriconazole, a substrate for CYP2C19/3A4, are increased during inflammation (59,60). As such, patients with inflammatory conditions may experience variation in pharmacokinetics of concomitant medication depending on the specific DME engaged in the drug's metabolic pathway. Our study suggests that drugs utilizing secondary or alternative routes via non-CYP clearance may be less susceptible to the effects of inflammation as compared with drugs fully metabolized by CYP enzymes.

In conclusion, our study has shown that UGT, FMO, and CES enzymes are less sensitive toward the effects of proinflammatory cytokines IL-6 and IL-1 β as compared with the CYP enzymes. Additionally, the findings highlight that transcriptional alterations in the DME expression are highly predictive for the alterations in enzyme activity, arguing against inflammation-related post-transcriptional modifications. Patients suffering from acute or chronic inflammatory diseases may thus be at risk for alterations in their drug metabolism, where the magnitude of the alteration likely depends on the DME family members involved in the clearance route of the drug.

Acknowledgements

The authors would like to thank and acknowledge Johan van der Reijden and Luuk Hawinkels (Department of Gastroenterology-Hepatology, Leiden University Medical Center) for their excellent support with acquiring and processing the human liver biopsies from the biobank.

References

1. Stanke-Labesque F, Gautier-Veyret E, Chhun S, Guilhaumou R. Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment. *Pharmacol Ther.* 2020 Nov 1;215.
2. Dunvald ACD, Järvinen E, Mortensen C, Stage TB. Clinical and Molecular Perspectives on Inflammation-Mediated Regulation of Drug Metabolism and Transport. *Clin Pharmacol Ther.* 2022 Aug 1;112(2):277–90.
3. Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation. *Annu Rev Pharmacol Toxicol.* 2006 Feb 10;46(1):123–49.
4. Dickmann LJ, Patel SK, C. Wienkers L, Greg Slatter J. Effects of Interleukin 1 β (IL-1 β) and IL-1 β /Interleukin 6 (IL-6) Combinations on Drug Metabolizing Enzymes in Human Hepatocyte Culture. *Curr Drug Metab.* 2012 Aug 2;13(7):930–7.
5. Dickmann LJ, Patel SK, Rock DA, Wienkers LC, Slatter JG. Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. *Drug Metab Dispos.* 2011 Aug 1;39(8):1415–22.
6. Tanner N, Kubik L, Luckert C, Thomas M, Hofmann U, Zanger UM, et al. Regulation of Drug Metabolism by the Interplay of Inflammatory Signaling, Steatosis, and Xeno-Sensing Receptors in HepaRG Cells. *Drug Metab Dispos.* 2018 Apr 1;46(4):326–35.
7. Klein M, Thomas M, Hofmann U, Seehofer D, Damm G, Zanger UM. A systematic comparison of the impact of inflammatory signaling on absorption, distribution, metabolism, and excretion gene expression and activity in primary human hepatocytes and HepaRG Cells. *Drug Metab Dispos.* 2015 Jan 1;43(2):273–83.
8. Leung JG, Nelson S, Takala CR, Gören JL. Infection and inflammation leading to clozapine toxicity and intensive care: a case series. *Ann Pharmacother.* 2014;48(6):801–5.
9. Xu Y, Hijazi Y, Wolf A, Wu B, Sun YN, Zhu M. Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity. *CPT pharmacometrics Syst Pharmacol.* 2015 Sep 1;4(9):507–15.
10. Stader F, Battegay M, Sendi P, Marzolini C. Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID-19 Patients. *Clin Pharmacol Ther.* 2022 Mar 1;111(3):579–84.
11. Machavaram KK, Almond LM, Rostami-Hodjegan A, Gardner I, Jamei M, Tay S, et al. A physiologically based pharmacokinetic modeling approach to predict disease-drug interactions: Suppression of CYP3A by IL-6. *Clin Pharmacol Ther.* 2013 Aug 1;94(2):260–8.
12. Lenoir C, Niederer A, Rollason V, Desmeules JA, Daali Y, Samer CF. Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics. *CPT pharmacometrics Syst Pharmacol.* 2022 Jan 1;11(1):30–43.
13. Jiang X, Zhuang Y, Xu Z, Wang W, Zhou H. Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6. *AAPS J.* 2016 Mar 9;18(3):767–76.
14. Ozbey AC, Fowler S, Leys K, Annaert P, Umehara K, Parrott N. PBPK Modelling for Drugs Cleared by Non-CYP Enzymes: State-of-the-Art and Future Perspectives. *Drug Metab Dispos.* 2023 Jan 1;52(1):44–55.
15. Saravanakumar A, Sadighi A, Ryu R, Akhlaghi F. Physicochemical Properties, Biotransformation, and Transport Pathways of Established and Newly Approved Medications: A Systematic Review of the Top 200 Most Prescribed Drugs vs. the FDA-Approved Drugs Between 2005 and 2016. *Clin Pharmacokinet.* 2019 Oct 1;58(10):1281–94.


16. de Jong LM, Jiskoot W, Swen JJ, Manson ML. Distinct effects of inflammation on cytochrome P450 regulation and drug metabolism: Lessons from experimental models and a potential role for pharmacogenetics. *Genes (Basel)*. 2020 Dec 1;11(12):1–24.
17. Coutant DE, Hall SD. Disease-Drug Interactions in Inflammatory States via Effects on CYP-Mediated Drug Clearance. *J Clin Pharmacol*. 2018 Jul 1;58(7):849–63.
18. Jablonska E, Jablonski J, Piotrowski L, Grabowska Z. IL-1 β , IL-1Ra and sIL-1RII in the culture supernatants of PMN and PBMC and the serum levels in patients with inflammation and patients with cancer disease of the same location. *Immunobiology*. 2001;204(4):508–16.
19. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, et al. Infection of a human hepatoma cell line by hepatitis B virus. *Proc Natl Acad Sci U S A*. 2002 Nov 26;99(24):15655–60.
20. de Jong LM, Boussallami S, Sánchez-López E, Giera M, Tushuizen ME, Hoekstra M, et al. The impact of CYP2C19 genotype on phenoconversion by concomitant medication. *Front Pharmacol*. 2023;14.
21. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem*. 1987 Apr;162(1):156–9.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 $^{-\Delta\Delta C_T}$ Method. *Methods*. 2001;25(4):402–8.
23. Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, Guguen-Guillouzo C. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. *Chem Biol Interact*. 2007 May 20;168(1):66–73.
24. Court MH, Krishnaswamy S, Hao Q, Duan SX, Patten CJ, Von Moltke LL, et al. Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. *Drug Metab Dispos*. 2003 Sep 1;31(9):1125–33.
25. Spaggiari D, Geiser L, Daali Y, Rudaz S. A cocktail approach for assessing the in vitro activity of human cytochrome P450s: an overview of current methodologies. *J Pharm Biomed Anal*. 2014 May 1;101:221–37.
26. Störmer E, Roots I, Brockmöller J. Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity. *Br J Clin Pharmacol*. 2000;50(6):553–61.
27. Sebaugh JL. Guidelines for accurate EC50/IC50 estimation. *Pharm Stat*. 2011 Mar;10(2):128–34.
28. Hines RN. Developmental and tissue-specific expression of human flavin-containing monooxygenases 1 and 3. *Expert Opin Drug Metab Toxicol*. 2006;2(1):41–9.
29. Izukawa T, Nakajima M, Fujiwara R, Yamanaka H, Fukami T, Takamiya M, et al. Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. *Drug Metab Dispos*. 2009 Aug;37(8):1759–68.
30. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Vol. 138, *Pharmacology and Therapeutics*. Pergamon; 2013. p. 103–41.
31. Klöditz K, Tewolde E, Nordling Å, Ingelman-Sundberg M. Mechanistic, Functional, and Clinical Aspects of Pro-inflammatory Cytokine Mediated Regulation of ADME Gene Expression in 3D Human Liver Spheroids. *Clin Pharmacol Ther*. 2023 Sep 1;114(3):673–85.
32. Kiamehr M, Heiskanen L, Laufer T, Dusterloh A, Kahraman M, Käkälä R, et al. Dedifferentiation of Primary Hepatocytes is Accompanied with Reorganization of Lipid Metabolism Indicated by Altered Molecular Lipid and miRNA Profiles. *Int J Mol Sci*. 2019 Jun 2;20(12).
33. Pinto C, Giordano DM, Maroni L, Marzioni M. Role of inflammation and proinflammatory cytokines in cholangiocyte pathophysiology. *Biochim Biophys Acta Mol basis Dis*. 2018 Apr 1;1864(4 Pt B):1270–8.

34. Nguyen T V., Ukaïro O, Khetani SR, McVay M, Kanchagar C, Seghezzi W, et al. Establishment of a hepatocyte-kupffer cell coculture model for assessment of proinflammatory cytokine effects on metabolizing enzymes and drug transporters. *Drug Metab Dispos.* 2015 May 1;43(5):774–85.
35. Xie W, Barwick JL, Simon CM, Pierce AM, Safe S, Blumberg B, et al. Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. *Genes Dev.* 2000;14(23):3014–23.
36. Ferguson SS, Lecluyse EL, Negishi M, Goldstein JA. Regulation of human CYP2C9 by the constitutive androstane receptor: Discovery of a new distal binding site. *Mol Pharmacol.* 2002 Sep 1;62(3):737–46.
37. Chen Y, Ferguson SS, Negishi M, Goldstein JA. Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. *Mol Pharmacol.* 2003 Aug 1;64(2):316–24.
38. Klick DE, Hines RN. Mechanisms regulating human FMO3 transcription. *Drug Metab Rev.* 2007 Apr;39(2–3):419–42.
39. Collins JM, Lu R, Wang X, Zhu HJ, Wang D. Transcriptional Regulation of Carboxylesterase 1 in Human Liver: Role of the Nuclear Receptor Subfamily 1 Group H Member 3 and Its Splice Isoforms. *Drug Metab Dispos.* 2022 Jan 1;50(1):43–8.
40. Hu DG, Meech R, McKinnon RA, Mackenzie PI. Transcriptional regulation of human UDP-glucuronosyltransferase genes. *Drug Metab Rev.* 2014 Nov 1;46(4):421–58.
41. Keller R, Klein M, Thomas M, Dräger A, Metzger U, Templin MF, et al. Coordinating Role of RXRa in Downregulating Hepatic Detoxification during Inflammation Revealed by Fuzzy-Logic Modeling. Altan-Bonnet G, editor. *PLOS Comput Biol.* 2016 Jan 4;12(1):e1004431.
42. Gramignoli R, Ranade AR, Venkataramanan R, Strom SC. Effects of Pro-Inflammatory Cytokines on Hepatic Metabolism in Primary Human Hepatocytes. *Int J Mol Sci.* 2022 Dec 1;23(23).
43. Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. *Sci Signal.* 2010 Jan 19;3(105).
44. Schaper F, Rose-John S. Interleukin-6: Biology, signaling and strategies of blockade. *Cytokine Growth Factor Rev.* 2015 Oct 1;26(5):475–87.
45. Ghose R, Zimmerman TL, Thevananthar S, Karpen SJ. Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: A novel mechanism for reduced hepatic gene expression in inflammation. *Nucl Recept.* 2004 Aug 16;2(1).
46. Ferrari L, Peng N, Halpert JR, Morgan ET. Role of nitric oxide in down-regulation of CYP2B1 protein, but not RNA, in primary cultures of rat hepatocytes. *Mol Pharmacol.* 2001;60(1):209–16.
47. Lee CM, Pohl J, Morgan ET. Dual mechanisms of CYP3A protein regulation by proinflammatory cytokine stimulation in primary hepatocyte cultures. *Drug Metab Dispos.* 2009 Apr;37(4):865–72.
48. Kugler N, Klein K, Zanger UM. MiR-155 and other microRNAs downregulate drug metabolizing cytochromes P450 in inflammation. *Biochem Pharmacol.* 2020 Jan 1;171.
49. Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. *Drug Metab Dispos.* 2007 Sep;35(9):1687–93.
50. Willmann S, Lippert J, Sevestre M, Solodenko J, Fois F, Schmitt W. PK-Sim®: A physiologically based pharmacokinetic “whole-body” model. *Drug Discov Today BIOSILICO.* 2003;1(4):121–4.
51. Machavaram KK, Endo-Tsukude C, Terao K, Gill KL, Hatley OJ, Gardner I, et al. Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations. *AAPS J.* 2019 May 1;21(3).
52. Kenny JR, Liu MM, Chow AT, Earp JC, Evers R, Slatter JG, et al. Therapeutic protein drug-drug interactions: navigating the knowledge gaps-highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA workshop. *AAPS J.* 2013;15(4):933–40.
53. Liu F, Aulin LBS, Manson ML, Krekels EHJ, van Hasselt JGC. Unraveling the Effects of Acute Inflammation on Pharmacokinetics: A Model-Based Analysis Focusing on Renal Glomerular Filtration Rate and Cytochrome P450 3A4-Mediated Metabolism. *Eur J Drug Metab Pharmacokinet.* 2023 Nov 1;48(6):623–31.


54. Song C, Long X, He J, Huang Y. Recent evaluation about inflammatory mechanisms in nonalcoholic fatty liver disease. *Front Pharmacol.* 2023;14.
55. Murphy WA, Adiwidjaja J, Sjöstedt N, Yang K, Beaudoin JJ, Spires J, et al. Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH). *Clin Pharmacol Ther.* 2023 Feb 1;113(2):275–97.
56. Powell NR, Liang T, Ipe J, Cao S, Skaar TC, Desta Z, et al. Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease. *Nat Commun.* 2023 Dec 1;14(1).
57. Govaere O, Cockell SJ, Zatorska M, Wonders K, Tiniakos D, Frey AM, et al. Pharmacogene expression during progression of metabolic dysfunction-associated steatotic liver disease: Studies on mRNA and protein levels and their relevance to drug treatment. *Biochem Pharmacol.* 2024 Oct;228:116249.
58. Mårtson AG, Veringa A, Bakker M, van den Heuvel ER, Touw DJ, van der Werf TS, et al. Posaconazole trough concentrations are not influenced by inflammation: A prospective study. *Int J Antimicrob Agents.* 2019 Mar 1;53(3):325–9.
59. Veringa A, ter Avest M, Span LFR, van den Heuvel ER, Touw DJ, Zijlstra JG, et al. Voriconazole metabolism is influenced by severe inflammation: A prospective study. *J Antimicrob Chemother.* 2017 Jan 1;72(1):261–7.
60. Van Wanrooy MJP, Span LFR, Rodgers MGG, Van Heuvel ERD, Uges DRA, Van Werf TSD, et al. Inflammation is associated with voriconazole trough concentrations. *Antimicrob Agents Chemother.* 2014 Dec 1;58(12):7098–101.

Supplemental information


Supplemental figures



Supplementary Figure S1 Cytokine concentration-response curves for regulation of CYP3A4, CYP2C9, CYP1A2, CYP2C19, FMO3 and UGT2B7 expression and activity by IL-6 (A) and IL-1β (B). Cells were treated with concentrations of 0.0001 ng/mL to 10 ng/mL (IL-6) or 0.001 pg/mL to 1 ng/mL (IL-1β) for 24 hours to analyze gene expression alterations via RT-qPCR or for 72 hours to analyze activity alterations via probe substrate metabolism with LC-MS/MS. mRNA and activity data are expressed as fold change of levels found in untreated control cells, arbitrarily set to 1.0. Each data point represents the average of at least 4 independent experiments ± SEM. Data was fit to a non-linear regression model in Graphpad Prism.



Supplementary Figure S2 Basal mRNA expression levels of DME regulating transcription factors and nuclear receptors in HepaRG cells. mRNA expression of the gene of interest was normalized to the housekeeping gene RPLP0, and presented as a fold change compared to basal CYP3A4 expression in HepaRG cells. All values are means + SEM from 8 independent experiments.



Supplementary Figure S3 Cytokine concentration-response curves for regulation of PXR and CAR as compared to CYP3A4. Cells were treated with concentrations of 0.0001 ng/ml to 10 ng/ml (IL-6) or 0.001 pg/ml to 1 ng/ml (IL-1 β) for 24 hours to analyze gene expression alterations via RT-qPCR. mRNA data is expressed as fold change of levels found in untreated control cells, arbitrary set to 1.0. Each data point presents the average + SEM of at least 4 independent experiments. Data were fit with a non-linear regression model.

Supplemental tables

Supplemental Table S1 Primer sequences

Sequence	
<i>CYP3A4</i>	For 5'-TGTGCTGGCTATCACAGATCCTGAC-3' Rev 5'-CAAAAGGCCTCCGGTTTGTGAAGAC-3'
<i>CYP2C19</i>	For 5'-AAAACCAAGGCTTCACCCTGTGATCC-3' Rev 5'-CCGGGAAATAATCAATGATAGTGGGAAA-3'
<i>CYP2C9</i>	For 5'-CTTTCCTCTGGGGCATTATCCATCTTTC-3' Rev 5'-CATAGGAAACTCTCCGTAATGGAGGTCCG-3'
<i>CYP1A2</i>	For 5'-GGTTCCTGTGGTTCCTGCAGAAAAC-3' Rev 5'-ATCTTCTCCTGTGGGATGAGGTTGC-3'
<i>FMO1</i>	For 5'-GGGCTCCATGATACCTACAGGAGAAAC-3' Rev 5'-CAGTAGCACAAAGCCAAACCAACTGG-3'
<i>FMO3</i>	For 5'-ATTCCACAGTTGACCTCCAGTCC-3' Rev 5'-GTCTCGCTTTTGCCAAACCATTTC-3'
<i>FMO4</i>	For 5'-TGGAGGCTACTGAAAAGGAACAGCTC-3' Rev 5'-TCCTTGAGGAACAGAAGTGGGATGC-3'
<i>UGT1A4</i>	For 5'-CCTGACAGCCTATGCTGTTCCA-3' Rev 5'-ATGCAGTAGCTCCACACAACACCT-3'
<i>UGT2B4</i>	For 5'-CCCTCCTTCCTATGTGCCTGTTGTTATG-3' Rev 5'-TCGAATAAGCCATATGTCAGCTTTTGCC-3'
<i>UGT2B7</i>	For 5'-CATGCAACAGATTAAGAGATGGTCAGACC-3' Rev 5'-CAGCAGCTCACTACAGGGAAAAATAGC-3'
<i>UGT2B15</i>	For 5'-TGGGACTCCTCCTTTATTTTCAGCATGG-3' Rev 5'-TGCTGCATCCAGTAACCTCGTCATTTAAC-3'
<i>NR1I2</i>	For 5'-GCAGGAGCAATTCGCCATTACTCTG-3' Rev 5'-TAGCAAAGGGGTGTATGTCTCTGGATG-3'
<i>NR1I3</i>	For 5'-TGCTTAGATGCTGGCATGAGGAAAG-3' Rev 5'-CTTGCTCCTTACTCAGTTGCACAGG-3'
<i>AHR</i>	For 5'-ATGTATCAGTGCCAGCCAGAACCTC-3' Rev 5'-AGTGGCTGAAGATGTGTGGTAGTCTG-3'
<i>RXRA</i>	For 5'-ATGCAGATGGACAAGACGGAGCTG-3' Rev 5'-AGGACGCATAGACCTTCTCCCTCAG-3'
<i>NR1H4</i>	For 5'-CGGAAATGGCAACCAATCATGTACAGG-3' Rev 5'-CAGACCCTTTCAGCAAAGCAATCTGG-3'
<i>HNF4A</i>	For 5'-AGAGATCCATGGTGTTCAGGACGTG-3' Rev 5'-CCTTGGCATCTGGGTCAAAGAAGATG-3'
<i>NFYA</i>	For 5'-CGTGGTGAAGGTGGACGATTTTTCTC-3' Rev 5'-TGTCATTGCTTCTTCATCGGCTTGG-3'
<i>USF1</i>	For 5'-ACAAGAAGTACTGCAGGGAGGAAGC-3' Rev 5'-CATTATGCTGAGCCCTGCGTTTCTC-3'

Supplemental materials and methods

LC-MS/MS method to quantify CYP activity

Quantification of acetaminophen, 4'hydroxymephentoin, 1'hydroxymidazolam, and 4'hydroxydiclofenac in cell supernatant was done using a liquid chromatography-tandem mass spectrometry (LC-MS/MS) system consisting of a Nexera LC-40 high-performance liquid chromatography (HPLC) system equipped with a DGU-403 degassing unit, two LC-40D pumps, a SIL-40C autosampler, and a CTO-40S column oven (Shimadzu, 's-Hertogenbosch, the Netherlands). A Kinetex C18 column (1.7 μ M, 50 $\times$ 2.1 mm) (Phenomenex, Utrecht, The Netherlands) with a SecurityGuard Ultra C18, 2.7 μ m, 5 $\times$ 2.1 mm cartridge (Phenomenex, Utrecht, The Netherlands) as guard column were used to separate probe metabolites from other analytes present in the sample matrix. Mobile phases consisted of water (A) and methanol (B) both containing 0.1% formic acid. The gradient, with a flow rate of 0.4 ml/min, started at 5% B and increased to 100% B in 4 min, maintaining 100% B for 2 min, and then returned to initial conditions for another 2 min. The column was kept at 50°C and the injection volume was 10 μ L or 20 μ L depending on the analyte. The HPLC was coupled to a Sciex QTRAP 6500+ mass spectrometer (AB Sciex Netherlands B.V., Nieuwerkerk aan den IJssel, The Netherlands) operating in positive electrospray mode (ESI+).

The MS conditions were as follows: curtain gas 20 psi, collision gas “medium”, ion source gas 1 40 psi, ion source gas 2 40 psi, ion spray voltage 5500 V and temperature 550°C. The MS was operated in the multiple reaction monitoring (MRM) mode and was optimized by direct infusion of the standards individually. The optimized MRM transitions, retention time, declustering potential (DP), collision energy (CE) and cell exit potential (CXP) used are summarized in Supplemental Table 2. Analyst software version 1.4 (AB Sciex Netherlands B.V., Nieuwerkerk aan den IJssel, The Netherlands) was used for data analysis.

Supplemental Table S2 MRM parameters and retention time for the quantified analytes by the LC-MS/MS method

Analyte	Q1 mass (Da)	Q3 mass (Da)	Retention time (min)	DP (V)	CE (V)	CXP (V)
Acetaminophen	152.1	110.0	1.37	46	23	12
Acetaminophen-d ₄	156.1	114.1	1.37	51	23	12
1'hydroxymidazolam	341.9	203.0	3.51	86	35	12
1'hydroxymidazolam-d ₄	345.9	203.0	3.51	81	37	16
4'-hydroxymephenytoin	235.1	150.1	2.70	51	25	10
4'-hydroxymephenytoin-d ₃	238.1	150.1	2.70	41	25	14
4'hydroxydiclofenac	312.0	230.0	4.02	46	43	12
4'hydroxydiclofenac- ¹³ C ₆	318.0	236.0	4.02	51	43	12

LC-MS/MS method to quantify FMO3 and UGT2B7 activity

Quantification of benzydamine N-oxide and morphine-3-glucuronide in cell supernatant was done using a liquid chromatography-tandem mass spectrometry (LC-MS/MS) system consisting of a Nexera-X2 ultra high-performance liquid chromatography (UHPLC) system equipped with a DGU-20A degassing unit, three LC-30 pumps, a SIL-30ACMP autosampler, and a CTO-30A column oven (Shimadzu, 's-Hertogenbosch, the Netherlands).

For benzydamine N-oxide, separation was achieved with an Acquity BEH column (1.7 μ m, 2.1 $\times$ 50 mm) from Waters (Etten-Leur, The Netherlands). Elution of benzydamine-N-oxide was performed using a high pressure gradient, with a flow of 0.4 ml/min, from 5% to 95% acetonitrile with 0.1% formic acid. The column was kept at 40°C and the injection volume was 10 μ L.

For morphine-3-glucuronide, separation as achieved with a Vision HT Basic column (3 μ m, 150 $\times$ 3 mm) (Grace, Breda, the Netherlands). An online solid-phase extraction (SPE) method was used to clean the samples, using a Hysphere GP cartridge (Spark Holland, Emmen, the Netherlands). Samples were injected into the SPE column and washed with 1 ml 10 mM ammonium acetate buffer at pH 10 for 1 minute to remove salts and other interferences, after which they were injected into the LC-column. Elution into the LC system was performed with a gradient of 3% to 97% acetonitrile with 0.1% formic acid in 4 minutes, at a flow of 300 μ L/min and re-equilibrated at 3% acetonitrile. The column was kept at 40°C and the injection volume was 5 μ L.

The UHPLC was coupled to a TSQ Vantage mass spectrometer (Thermo Fisher, Breda, The Netherlands) operating in positive electrospray mode (ESI+). The MS conditions were as follows: curtain gas 20 psi, collision gas 0.5 atm ion source gas 5 psi, ion spray voltage 3000 V and temperature 350°C. The MS was operated in MRM mode and was optimized by direct infusion of the standards individually. The optimized MRM transitions, retention time, declustering potential (DP) and collision energy (CE) used for both analytes are summarized in Supplemental Table 3. Thermo XCalibur Software LCQuan 2.7 was used for data analysis.

Supplemental Table S3 MRM parameters and retention time for the quantified analytes by the LC-MS/MS method

Analyte	Q1 mass (Da)	Q3 mass (Da)	Retention time (min)	DP (V)	CE (V)
Benzydamine N-oxide	326.2	102.1	4.5	16	9
Benzydamine N-oxide-d ₆	332.2	108.2	4.5	16	8
Morphine-3-glucuronide	462.1	152.9, 201.0, 286.113	4.4	6	62, 48 and 24
Morphine-3-glucuronide-d ₃	465.2	152.9, 201.0, 289.074	4.4	6	62, 48 and 24